Antitumor effects of guanosine-analog phosphonates identified by molecular modelling

International Journal of Pharmaceutics

Volumn 397, Issue 1-2, 2010, Pages 9-18

  Schwanke, Anja ^a   Murruzzu, Caterina ^a   Zdrazil, Barbara ^b   Zuhse, Ralf ^c   Natek, Maja ^a   Höltje, Monika ^b   Korting, Hans Christian ^d   Reissig, Hans Ulrich ^a   Höltje, Hans Dieter ^b   Schäfer Korting, Monika ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c Chiracon GmbH   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Human DNA polymerase alpha; Keratinocytes; Nucleotide analogs; Polymerase inhibitors; Skin cancer; Tumor cell lines

Indexed keywords

ANTINEOPLASTIC AGENT; APHIDICOLIN; DNA DIRECTED DNA POLYMERASE ALPHA; FLUOROURACIL; GUANOSINE DERIVATIVE; OXBU; OXHEX; PHOSPHONIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MOLECULAR MODEL; PRIORITY JOURNAL; SKIN CELL;

ADENINE; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; FLUOROURACIL; HT29 CELLS; HUMANS; KERATINOCYTES; KERATOSIS, ACTINIC; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; PHOSPHONIC ACIDS;

EID: 77955985205     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.06.036     Document Type: Article

References (55)

1. Andersson K., Waterboer T., Kirnbauer R., Slupetzky K., Iftner T., de Villiers E.M., Forslund O., Pawlita M., Dillner J. Seroreactivity to cutaneous human papillomaviruses among patients with nonmelanoma skin cancer or benign skin lesions. Cancer Epidemiol. Biomark. Prev. 2008, 17:189-195.
2. Anwar J., Wrone D.A., Kimyai-Asadi A., Alam M. The development of actinic keratosis into invasive squamous cell carcinoma: evidence and evolving classification schemes. Clin. Dermatol. 2004, 22:189-196.
3. Bailey W.F., Zarcone L.M.J., Rivera A.D. Selective protection of 1,2- and 1,3-diols via acylative cleavage of cyclic formals. J. Org. Chem. 1995, 60:2532-2536.
4. Boucher P.D., Im M.M., Freytag S.O., Shewach D.S. A novel mechanism of synergistic cytotoxicity with 5-fluorocytosine and ganciclovir in double suicide gene therapy. Cancer Res. 2006, 66:3230-3237.
5. Buckman S.Y., Gresham A., Hale P., Hruza G., Anast J., Masferrer J., Pentland A.P. COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis 1998, 19:723-729.
6. Challacombe J.M., Suhrbier A., Parsons P.G., Jones B., Hampson P., Kavanagh D., Rainger G.E., Morris M., Lord J.M., Le T.T., Hoang-Le D., Ogbourne S.M. Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate. J. Immunol. 2006, 177:8123-8132.
7. Chen W., Flavin M.T., Filler R., Xu Z.-Q. An improved synthesis of 9-[2-(diethoxyphosphonomethoxy)ethyl]adenine and its analogues with other purine bases utilizing the mitsunobu reaction. Nucleosides Nucleotides 1996, 15:1771-1778.
8. Dianzani C., Pierangeli A., Chiricozzi A., Avola A., Degener A.M. Cutaneous human papillomaviruses as recurrence factor in actinic keratoses. Int. J. Immunopathol. Pharmacol. 2008, 21:145-152.
9. Eriksson S., Munch-Petersen B., Johansson K., Eklund H. Structure and function of cellular deoxyribonucleoside kinases. Cell. Mol. Life Sci. 2002, 59:1327-1346.
10. Gandhi V., Huang P., Chapman A.J., Chen F., Plunkett W. Incorporation of fludarabine and 1-beta-d-arabinofuranosylcytosine 5'-triphosphates by DNA polymerase alpha: affinity, interaction, and consequences. Clin. Cancer Res. 1997, 3:1347-1355.
11. Gupta A.K., Davey V., McPhail H. Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: critical review and meta-analysis of efficacy studies. J. Cutan. Med. Surg. 2005, 9:209-214.
12. Gysler A., Lange K., Korting H.C., Schäfer-Korting M. Prednicarbate biotransformation in human foreskin keratinocytes and fibroblasts. Pharm. Res. 1997, 14:793-797.
13. Haberland A., Schreiber S., Maia C.S., Rübbelke M.K., Schaller M., Korting H.C., Kleuser B., Schimke I., Schäfer-Korting M. The impact of skin viability on drug metabolism and permeation - BSA toxicity on primary keratinocytes. Toxicol. In Vitro 2006, 20:347-354.
14. Höltje M., Richartz A., Zdrazil B., Schwanke A., Dugovic B., Murruzzu C., Reissig H.U., Korting H.C., Kleuser B., Höltje H.D., Schäfer-Korting M. Human polymerase alpha inhibitors for skin tumors. Part 2. Modeling, synthesis and influence on normal and transformed keratinocytes of new thymidine and purine derivatives. J. Enzyme Inhib. Med. Chem. 2010, 25:250-265.
15. Jenning V., Schäfer-Korting M., Gohla S. Vitamin A-loaded solid lipid nanoparticles for topical use: drug release properties. J. Control Release 2000, 66:115-126.
16. Jiang H.Y., Hickey R.J., Abdel-Aziz W., Malkas L.H. Effects of gemcitabine and araC on in vitro DNA synthesis mediated by the human breast cell DNA synthesome. Cancer Chemother. Pharmacol. 2000, 45:320-328.
17. Jorizzo J. Topical treatment of actinic keratosis with fluorouracil: is irritation associated with efficacy?. J. Drugs Dermatol. 2004, 3:21-26.
18. Jorizzo J., Stewart D., Bucko A., Davis S.A., Espy P., Hino P., Rodriguez D., Savin R., Stough D., Furst K., Connolly M., Levy S. Randomized trial evaluating a new 0.5% fluorouracil formulation demonstrates efficacy after 1-, 2-, or 4-week treatment in patients with actinic keratosis. Cutis 2002, 70:335-339.
19. Jorizzo J.L. Current and novel treatment options for actinic keratosis. J. Cutan. Med. Surg. 2004, 8(Suppl. 3):13-21.
20. Korting, H.C., Schäfer-Korting, M., 2009. Carriers in the topical treatment of skin disease. In: Schäfer-Korting, M. (Ed.), Handbook of Experimental Pharmacology, Vol. 197 Drug Delivery, Springer, Heidelberg, pp. 435-468.
21. Küchler S., Radowski M.R., Blaschke T., Dathe M., Plendl J., Haag R., Schäfer-Korting M., Kramer K.D. Nanoparticles for skin penetration enhancement - a comparison of a dendritic core-multishell-nanotransporter and solid lipid nanoparticles. Eur. J. Pharm. Biopharm. 2009, 71:243-250.
22. Kuriyama I., Musumi K., Yonezawa Y., Takemura M., Maeda N., Iijima H., Hada T., Yoshida H., Mizushina Y. Inhibitory effects of glycolipids fraction from spinach on mammalian DNA polymerase activity and human cancer cell proliferation. J. Nutr. Biochem. 2005, 16:594-601.
23. Lebwohl M., Dinehart S., Whiting D., Lee P.K., Tawfik N., Jorizzo J., Lee J.H., Fox T.L. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J. Am. Acad. Dermatol. 2004, 50:714-721.
24. Levy S., Furst K., Chern W. A comparison of the skin permeation of three topical 0.5% fluorouracil formulations with that of a 5% formulation. Clin. Ther. 2001, 23:901-907.
25. Lombardi Borgia S., Regehly M., Sivaramakrishnan R., Mehnert W., Korting H.C., Danker K., Röder B., Kramer K.D., Schäfer-Korting M. Lipid nanoparticles for skin penetration enhancement-correlation to drug localization within the particle matrix as determined by fluorescence and parelectric spectroscopy. J. Control Release 2005, 110:151-163.
26. Maeda N., Kokai Y., Ohtani S., Sahara H., Hada T., Ishimaru C., Kuriyama I., Yonezawa Y., Iijima H., Yoshida H., Sato N., Mizushina Y. Anti-tumor effects of the glycolipids fraction from spinach which inhibited DNA polymerase activity. Nutr. Cancer 2007, 57:216-223.
27. Maeda N., Kokai Y., Ohtani S., Sahara H., Kuriyama I., Kamisuki S., Takahashi S., Sakaguchi K., Sugawara F., Yoshida H., Sato N., Mizushina Y. Anti-tumor effects of dehydroaltenusin, a specific inhibitor of mammalian DNA polymerase alpha. Biochem. Biophys. Res. Commun. 2007, 352:390-396.
28. Manggau M., Kim D.S., Ruwisch L., Vogler R., Korting H.C., Schäfer-Korting M., Kleuser B. 1Alpha,25-dihydroxyvitamin D3 protects human keratinocytes from apoptosis by the formation of sphingosine-1-phosphate. J. Invest. Dermatol. 2001, 117:1241-1249.
29. Matsubara K., Saito A., Tanaka A., Nakajima N., Akagi R., Mori M., Mizushina Y. Catechin conjugated with fatty acid inhibits DNA polymerase and angiogenesis. DNA Cell Biol. 2006, 25:95-103.
30. Matsubara K., Saito A., Tanaka A., Nakajima N., Akagi R., Mori M., Mizushina Y. Epicatechin conjugated with fatty acid is a potent inhibitor of DNA polymerase and angiogenesis. Life Sci. 2007, 80:1578-1585.
31. Miller R.L., Meng T.C., Tomai M.A. The antiviral activity of Toll-like receptor 7 and 7/8 agonists. Drug News Perspect. 2008, 21:69-87.
32. Ngawhirunpat T., Kawakami N., Hatanaka T., Kawakami J., Adachi I. Age dependency of esterase activity in rat and human keratinocytes. Biol. Pharm. Bull. 2003, 26:1311-1314.
33. Pariser D., Loss R., Jarratt M., Abramovits W., Spencer J., Geronemus R., Bailin P., Bruce S. Topical methyl-aminolevulinate photodynamic therapy using red light-emitting diode light for treatment of multiple actinic keratoses: a randomized, double-blind, placebo-controlled study. J. Am. Acad. Dermatol. 2008, 59:569-576.
34. Park P., Copeland W., Yang L., Wang T., Botchan M.R., Mohr I.J. The cellular DNA polymerase alpha-primase is required for papillomavirus DNA replication and associates with the viral E1 helicase. Proc. Natl. Acad. Sci. USA 1994, 91:8700-8704.
35. Perry C.M., Lamb H.M. Topical imiquimod: a review of its use in genital warts. Drugs 1999, 58:375-390.
36. Richartz A., Höltje M., Brandt B., Schäfer-Korting M., Höltje H.D. Targeting human DNA polymerase alpha for the inhibition of keratinocyte proliferation. Part 1. Homology model, active site architecture and ligand binding. J. Enzyme Inhib. Med. Chem. 2008, 23:94-100.
37. Rivers J.K., Arlette J., Shear N., Guenther L., Carey W., Poulin Y. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br. J. Dermatol. 2002, 146:94-100.
38. Santos Maia C., Mehnert W., Schaller M., Korting H.C., Gysler A., Haberland A., Schäfer-Korting M. Drug targeting by solid lipid nanoparticles for dermal use. J. Drug Target. 2002, 10:489-495.
39. Schäfer-Korting M., Höltje M., Korting H.C., Höltje H.D. Innovative agents for actinic keratosis and nanocarriers enhancing skin penetration. Skin Pharmacol. Physiol. 2010, 23:6-14.
40. Schäfer-Korting M., Mehnert W., Korting H.C. Lipid nanoparticles for improved topical application of drugs for skin diseases. Adv. Drug Deliv. Rev. 2007, 59:427-443.
41. Sessa C., Zucchetti M., Davoli E., Califano R., Cavalli F., Frustaci S., Gumbrell L., Sulkes A., Winograd B., D'Incalci M. Phase I and clinical pharmacological evaluation of aphidicolin glycinate. J. Natl. Cancer Inst. 1991, 83:1160-1164.
42. Siller G., Gebauer K., Welburn P., Katsamas J., Ogbourne S.M. PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study. Australas. J. Dermatol. 2009, 50:16-22.
43. Spadari S., Maga G., Verri A., Focher F. Molecular basis for the antiviral and anticancer activities of unnatural l-beta-nucleosides. Expert Opin. Investig. Drugs 1998, 7:1285-1300.
44. Stecova J., Mehnert W., Blaschke T., Kleuser B., Sivaramakrishnan R., Zouboulis C.C., Seltmann H., Korting H.C., Kramer K.D., Schäfer-Korting M. Cyproterone acetate loading to lipid nanoparticles for topical acne treatment: particle characterisation and skin uptake. Pharm. Res. 2007, 24:991-1000.
45. Stockfleth, E., 2008. Aktinische Keratose, AWMF-Leitlinien. AWMF.
46. Stockfleth E., Kerl H. Guidelines for the management of actinic keratoses. Eur. J. Dermatol. 2006, 16:599-606.
47. Stockfleth E., Meyer T., Benninghoff B., Salasche S., Papadopoulos L., Ulrich C., Christophers E. A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. Arch. Dermatol. 2002, 138:1498-1502.
48. Tetko I.V., Tanchuk V.Y. Application of associative neural networks for prediction of lipophilicity in ALOGPS 2.1 program. J. Chem. Inf. Comput. Sci. 2002, 42:1136-1145.
49. Tetko I.V., Tanchuk V.Y., Villa A.E. Prediction of n-octanol/water partition coefficients from PHYSPROP database using artificial neural networks and E-state indices. J. Chem. Inf. Comput. Sci. 2001, 41:1407-1421.
50. Vasiljevic N., Hazard K., Dillner J., Forslund O. Four novel human betapapillomaviruses of species 2 preferentially found in actinic keratosis. J. Gen. Virol. 2008, 89:2467-2474.
51. Vogler R., Sauer B., Kim D.S., Schäfer-Korting M., Kleuser B. Sphingosine-1-phosphate and its potentially paradoxical effects on critical parameters of cutaneous wound healing. J. Invest. Dermatol. 2003, 120:693-700.
52. Weinstock M.A. Controversies in the public health approach to keratinocyte carcinomas. Br. J. Dermatol. 2006, 154(Suppl. 1):3-4.
53. Weissenborn S.J., De Koning M.N., Wieland U., Quint W.G., Pfister H.J. Intrafamilial transmission and family-specific spectra of cutaneous betapapillomaviruses. J. Virol. 2009, 83:811-816.
54. Weissenborn S.J., Nindl I., Purdie K., Harwood C., Proby C., Breuer J., Majewski S., Pfister H., Wieland U. Human papillomavirus-DNA loads in actinic keratoses exceed those in non-melanoma skin cancers. J. Invest. Dermatol. 2005, 125:93-97.
55. Zdrazil, B., Schwanke, A., Schmitz, B., Schäfer-Korting, M., Höltje, H.D. Molecular modeling studies of new potential human DNA polymerase alpha inhibitors. J. Enzyme Inhib. Med. Chem., in press.